Alembic Pharmaceuticals Ltd. (APLLTD) fundamentals
Alembic Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as APLLTD (ISIN INE901L01018). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Alembic Pharmaceuticals Ltd. does
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its Indian Formulations.
Valuation and market data
| Last close | ₹766.40 |
|---|---|
| Market capitalisation | ₹14,976 crore |
| Enterprise value | ₹15,279 crore |
| P/E (TTM) | 22.32 |
| Price to book | 2.64 |
| Price to sales (TTM) | 1.12 |
| Book value per share | ₹290.11 |
| Dividend yield | 156.58% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Sep 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹7,399 crore | ₹694 crore | ₹671 crore | 34.33 |
| Mar 2025 | ₹6,715 crore | ₹707 crore | ₹582 crore | 29.68 |
| Mar 2024 | ₹6,257 crore | ₹632 crore | ₹616 crore | 31.33 |
| Mar 2023 | ₹5,655 crore | ₹355 crore | ₹342 crore | 17.40 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 69.9% |
|---|---|
| Foreign institutions (FII) | 4.5% |
| Mutual funds | 8.5% |
| Other domestic institutions | 6.9% |
| Retail and others | 10.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.